Key result
Elevated Lp(a) affects ~20% globally and drives ASCVD risk, especially in T2DM and obesity.
Why the study?
Lipoprotein(a) is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease with complex relevance in patients with type 2 diabetes and obesity.
Lipoprotein(a) is highlighted as a key contributor to residual atherogenic risk in patients with type 2 diabetes and obesity, even when LDL-C targets are met.
Lipoprotein(a) [Lp(a)] is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis, with elevated levels found in approximately 20% of the global population. Unlike most lipid parameters, Lp(a) is largely unaffected by lifestyle modification or statin therapy, making it one of the main contributors to residual atherogenic risk even when target LDL-cholesterol levels are achieved. Lp(a) acquires particular clinical relevance in patients with type 2 diabetes mellitus (T2DM) and obesity — a population with inherently elevated cardiometabolic risk, in whom its relationship with Lp(a) is complex.
No takes yet. Share an insight, caveat, or question.
D.K. et al. (2026) conducted a review in Type 2 diabetes mellitus and obesity. Lipoprotein(a) was evaluated. Elevated Lipoprotein(a) levels, found in approximately 20% of the global population, act as an independent risk factor for atherosclerotic cardiovascular disease, particularly in T2DM and obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: